16 results on '"Santachiara, R."'
Search Results
2. Random ballistic growth and diffusion in symmetric spaces
- Author
-
Gorsky, A., Nechaev, S., Santachiara, R., and Schehr, G.
- Subjects
Mathematical Physics ,Condensed Matter - Statistical Mechanics ,Mathematics - Probability - Abstract
Sequential ballistic deposition (BD) with next-nearest-neighbor (NNN) interactions in a N-column box is viewed a time-ordered product of N\times N-matrices consisting of a single sl_2-block which has a random position along the diagonal. We relate the uniform BD growth with the diffusion in the symmetric space H_N=SL(N,R)/SO(N). In particular, the distribution of the maximal height of a growing heap is connected with the distribution of the maximal distance for the diffusion process in H_N. The coordinates of H_N are interpreted as the coordinates of particles of the one--dimensional Toda chain. The group-theoretic structure of the system and links to some random matrix models are also discussed., Comment: 29 pages, 7 figures. Revised and published version. To appear in Nuclear Physics B
- Published
- 2011
- Full Text
- View/download PDF
3. Universality of coupled Potts models
- Author
-
Dotsenko, Vl. S., Jacobsen, J. L., Nguyen, X. S., and Santachiara, R.
- Subjects
Condensed Matter - Statistical Mechanics - Abstract
We study systems of M Potts models coupled by their local energy density. Each model is taken to have a distinct number of states, and the permutational symmetry S_M present in the case of identical coupled models is thus broken initially. The duality transformations within the space of 2^M-1 multi-energy couplings are shown to have a particularly simple form. The selfdual manifold has dimension D_M = 2^{M-1}-1. Specialising to the case M=3, we identify a unique non-trivial critical point in the three-dimensional selfdual space. We compare its critical exponents as computed from the perturbative renormalisation group with numerical transfer matrix results. Our main objective is to provide evidence that at the critical point of three different coupled models the symmetry S_3 is restored., Comment: 29 pages, 3 figures
- Published
- 2001
- Full Text
- View/download PDF
4. On-site magnetization in open antiferromagnetic chains: a classical analysis versus NMR experiments in a spin-1 compound
- Author
-
Botti, S., Rosso, A., Santachiara, R., and Tedoldi, F.
- Subjects
Condensed Matter - Strongly Correlated Electrons - Abstract
The response of an open spin chain with isotropic antiferromagnetic interactions to a uniform magnetic field is studied by classical Monte Carlo simulations. It is observed how the induced on-site magnetization is non uniform, due to the occurrence of edge staggered terms which decay exponentially over a distance equal to the zero field correlation length of the infinite chain. The total magnetic moment associated to each staggered term is found to be about half of the original single-spin magnitude and to decrease as the inverse of temperature (i.e. to behave as a Curie-like moment). The numerical results are compared to recent NMR findings in spinless-doped Y(2)BaNiO(5); the remarkable agreement found shows that, for temperatures above the Haldane gap, the classical approach gives a correct picture of the boundary effects observed in the Heisenberg S=1 chain., Comment: 4 pages, 4 eps figures; minor changes in the text; added references
- Published
- 2000
- Full Text
- View/download PDF
5. Y NMR imaging of the staggered magnetization in doped Haldane chain Y(2)BaNi(1-x)Mg(x)O(5)
- Author
-
Tedoldi, F., Santachiara, R., and Horvatic, M.
- Subjects
Condensed Matter - Strongly Correlated Electrons - Abstract
We present a static, model-independent, experimental determination of the spin-spin correlation length \xi in a quantum spin system. This is achieved in doped Haldane (i.e., S=1 Heisenberg antiferromagnetic) chain Y(2)BaNi(1-x)Mg(x)O(5) by Y NMR imaging of the staggered magnetization induced around the Mg-impurities (i.e., chain boundaries) by magnetic field. The magnitude of this magnetization is found to decay exponentially with \xi equal to the theoretical prediction for an infinite S=1 chain, and the staggered magnetic moment at the edge site showing the Curie behavior of an effective S=1/2 spin., Comment: 4 pages, 3 eps figures; changes in introduction and references
- Published
- 1999
- Full Text
- View/download PDF
6. Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status
- Author
-
Maffei, R, Marasca, R, Martinelli, S, Castelli, I, Santachiara, R, Morandi, E, Zucchini, P, Fontana, M, Giacobbi, F, Silingardi, P, Bonacorsi, G, Temperani, P, Masini, L, Colacci, A M, Serra, R, and Torelli, G
- Published
- 2007
- Full Text
- View/download PDF
7. AGT, N-Burge partitions and WN minimal models
- Author
-
Belavin, V, Foda, O, Santachiara, R, Belavin, V, Foda, O, and Santachiara, R
- Abstract
Let ${\mathcal B}^{\, p, \, p^{\prime}, \, {\mathcal H}}_{N, n}$ be a conformal block, with $n$ consecutive channels $\chi_{\i}$, $\i = 1, \cdots, n$, in the conformal field theory $\mathcal{M}^{\, p, \, p^{\prime}}_N \! \times \! \mathcal{M}^{\mathcal{H}}$, where $\mathcal{M}^{\, p, \, p^{\prime}}_N$ is a $\mathcal{W}_N$ minimal model, generated by chiral fields of spin $1, \cdots, N$, and labeled by two co-prime integers $p$ and $p^{\prime}$, $1 < p < p^{\prime}$, while $\mathcal{M}^{\mathcal{H}}$ is a free boson conformal field theory. $\mathcal{B}^{\, p, \, p^{\prime}, \mathcal{H}}_{N, n}$ is the expectation value of vertex operators between an initial and a final state. Each vertex operator is labelled by a charge vector that lives in the weight lattice of the Lie algebra $A_{N-1}$, spanned by weight vectors $\omega_1, \cdots, \omega_{N-1}$. We restrict our attention to conformal blocks with vertex operators whose charge vectors point along $\omega_1$. The charge vectors that label the initial and final states can point in any direction. Following the $\mathcal{W}_N$ AGT correspondence, and using Nekrasov's instanton partition functions without modification, to compute $\mathcal{B}^{\, p, \, p^{\prime}, \mathcal{H}}_{N, n}$, leads to ill-defined expressions. We show that restricting the states that flow in the channels $\chi_{\i}$, $\i = 1, \cdots, n$, to states labeled by $N$ partitions that satisfy conditions that we call $N$-Burge partitions, leads to well-defined expressions that we identify with $\mathcal{B}^{\, p, \, p^{\prime}, \, \mathcal{H}}_{N, n}$. We check our identification by showing that a specific non-trivial conformal block that we compute, using the $N$-Burge conditions satisfies the expected differential equation.
- Published
- 2015
8. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia
- Author
-
Rinaldi, A., Mian, M., Kwee, I., Rossi, D., Deambrogi, C., Mensah, A. A., Forconi, Francesco, Spina, V., Cencini, E., Drandi, D., Ladetto, M., Santachiara, R., Marasca, R., Gattei, V., Cavalli, F., Zucca, E., Gaidano, G., and Bertoni, F.
- Subjects
Adult ,Male ,Adult, Aged, Aged ,80 and over, Comparative Genomic Hybridization, DNA Fingerprinting, Female, Genome-Wide Association Study, Humans, Leukemia ,Lymphocytic ,Chronic ,B-Cell ,diagnosis/genetics/mortality, Male, Middle Aged, Multivariate Analysis, Mutation, Neural Networks (Computer), Prognosis, Survival Rate, Young Adult ,Young Adult ,80 and over ,Humans ,Chronic Lymphocytic Leukemia ,Aged ,Aged, 80 and over ,Comparative Genomic Hybridization ,Leukemia ,gene deletion ,diagnosis/genetics/mortality ,prognosis ,Neural Networks (Computer) ,Middle Aged ,Prognosis ,DNA Fingerprinting ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Rate ,Multivariate Analysis ,Mutation ,Female ,Neural Networks, Computer ,Genome-Wide Association Study - Abstract
The integration of molecular and clinical information to tailor treatments remains an important research challenge in chronic lymphocytic leukaemia (CLL). This study aimed to identify genomic lesions associated with a poor outcome and a higher risk of histological transformation. A mono-institutional cohort of 147 cases was used as the test series, and a multi-institutional cohort of 176 cases as a validation series. Genomic profiles were obtained using Affymetrix SNP 6.0. The impact of the recurrent minimal common regions (MCRs) on overall survival was evaluated by univariate analysis followed by multiple-test correction. The independent prognostic significance was assessed by multivariate analysis. Eight MCRs showed a prognostic impact: gains at 2p25.3-p22.3 (MYCN), 2p22.3, 2p16.2-p14 (REL), 8q23.3-q24.3 (MYC), losses at 8p23.1-p21.2, 8p21.2, and of the TP53 locus. Gains at 2p and 8q and TP53 inactivation maintained prognostic significance in multivariate analysis and a hierarchical model confirmed their relevance. Gains at 2p also determined a higher risk of Richter syndrome transformation. The prediction of outcome for CLL patients might be improved by evaluating the presence of gains at 2p and 8q as novel genomic regions besides those included in the 'standard' fluorescence in situ hybridization panel.
- Published
- 2011
9. Pregnancy in PNH: another eculizumab baby
- Author
-
Marasca, Roberto, Coluccio, Valeria, Santachiara, R, Leonardi, G, Torelli, Giuseppe, Notaro, R, and Luzzatto, L.
- Subjects
PNH ,eculizumab ,pregnancy - Published
- 2010
10. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia
- Author
-
Maffei, R, Fiorcari, S, Bulgarelli, J, Rizzotto, L, Martinelli, S, Rigolin, Gm, Debbia, G, Castelli, I, Bonacorsi, G, Santachiara, R, Forconi, F, Rossi, D, Laurenti, Luca, Palumbo, Ga, Vallisa, D, Cuneo, A, Gaidano, G, Luppi, M, Marasca, R., Laurenti, Luca (ORCID:0000-0002-8327-1396), Maffei, R, Fiorcari, S, Bulgarelli, J, Rizzotto, L, Martinelli, S, Rigolin, Gm, Debbia, G, Castelli, I, Bonacorsi, G, Santachiara, R, Forconi, F, Rossi, D, Laurenti, Luca, Palumbo, Ga, Vallisa, D, Cuneo, A, Gaidano, G, Luppi, M, Marasca, R., and Laurenti, Luca (ORCID:0000-0002-8327-1396)
- Abstract
Lenalidomide is an IMID immunomodulatory agent clinically active in patients with chronic lymphocytic leukemia (CLL). We evaluated the activity of lenalidomide inside an in vitro coculture system of endothelial and CLL cells. Lenalidomide was able to inhibit CLL survival advantage mediated by endothelial contact. Moreover, the marked increase of in vitro angiogenesis determined by CLL-derived conditioned media was reduced by lenalidomide. We also analyzed peripheral blood collected from 27 patients with relapsed/refractory CLL being treated with lenalidomide within a phase II trial. Plasma levels of VEGF and THBS-1 decreased, whereas Ang2 and Ang increased during treatment. Patients who respond to lenalidomide showed a more pronounced decrease of VEGF and bFGF than did patients with stable or progressive disease (p = 0.007 and p = 0.005). Furthermore, lenalidomide reduced circulating endothelial cells and endothelial progenitors by increasing the percentage of apoptotic cells. Conversely, for six matched bone marrow biopsies available before and after treatment, we did not detect any modification in vessel density, suggesting a possible mechanism of vessel normalization rather than regression. In conclusion, our study provides further evidence that the anti-CLL effect of lenalidomide is mediated through the alteration of microenvironmental elements, implying the modulation of several angiogenesis-related factors and disruption of CLL crosstalk with endothelial cells.
- Published
- 2014
11. SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI
- Author
-
Santachiara, R., Leonardi, G., Vallisa, D., Maffei, R., Martinelli, S., Ferrari, A., Alfieri, P., Luppi, G., Bertolini, F., Piacentini, F., Marasca, R., and Torelli, G.
- Published
- 2007
12. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor
- Author
-
Santachiara, R., primary, Maffei, R., additional, Martinelli, S., additional, Arcari, A., additional, Piacentini, F., additional, Trabacchi, E., additional, Alfieri, P., additional, Ferrari, A., additional, Leonardi, G., additional, Luppi, G., additional, Longo, G., additional, Vallisa, D., additional, Marasca, R., additional, and Torelli, G., additional
- Published
- 2008
- Full Text
- View/download PDF
13. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia
- Author
-
Davide Rossi, Patrizia Zucchini, Gianluca Gaidano, Rita Santachiara, Stefania Fiorcari, Gian Matteo Rigolin, Ilaria Castelli, Silvia Martinelli, Valter Gattei, Claudio Tripodo, Giovanna Leonardi, Rossana Maffei, Giovanni Del Poeta, Carla Guarnotta, Francesco Forconi, Giuseppe Torelli, Antonio Cuneo, Marcella Fontana, Valeria Coluccio, Elisa Sozzi, Roberto Marasca, Antonella Zucchetto, Maffei, R, Martinelli, S, Santachiara, R, Rossi, D, Guarnotta, C, Sozzi, E, Zucchetto, A, Rigolin, GM, Fiorcari, S, Castelli, I, Fontana, M, Coluccio, V, Leonardi, G, Zucchini, P, Tripodo, C, Cuneo, A, Gattei, V, Del Poeta, G, Forconi, F, Gaidano, G, Torelli, G, and Marasca, R
- Subjects
glycoprotein ,Male ,Time Factors ,ZAP-70 ,Chronic lymphocytic leukemia ,vascular endothelial growth factor a ,Biochemistry ,Gastroenterology ,immunoglobulin heavy chains ,Adult, Aged, Aged ,80 and over, Angiopoietin-2 ,analysis/blood, Blood Chemical Analysis, Female, Humans, Leukemia ,Lymphocytic ,Chronic ,B-Cell ,blood/diagnosis/mortality/therapy, Male, Middle Aged, Neoadjuvant Therapy, Prognosis, Survival Analysis, Time Factors, Tumor Markers ,Biological ,blood ,Blood plasma ,80 and over ,Tumor Markers ,Aged, 80 and over ,Leukemia ,Hematology ,Hazard ratio ,protein kinase ,analysis/blood ,Middle Aged ,chronic b-cell leukemias ,Prognosis ,Neoadjuvant Therapy ,Cohort ,Female ,Adult ,medicine.medical_specialty ,Immunology ,angiopoietins, chronic b-cell leukemias, chronic lymphocytic leukemia, plasma, vascular endothelial growth factor a, cd38, enzyme-linked immunosorbent assay, glycoprotein, immunoglobulin heavy chains, protein kinase ,NO ,cd38 ,Angiopoietin-2 ,Internal medicine ,medicine ,Biomarkers, Tumor ,chronic lymphocytic leukemia, angiopoietin-2 ,Humans ,beta(2)-microglobulin ,plasma ,Survival analysis ,blood/diagnosis/mortality/therapy ,Aged ,business.industry ,Cell Biology ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Analysis ,Confidence interval ,chronic lymphocytic leukemia ,angiopoietin-2 ,enzyme-linked immunosorbent assay ,business ,CLL ,CD38 ,Settore MED/15 - Malattie del Sangue ,angiopoietins ,Blood Chemical Analysis ,Tumor Markers, Biological - Abstract
The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive of reduced TTFT (P < .001) and overall survival (P = .002). Multivariate analysis confirmed that high Ang2 was an independent prognosticator for TTFT (hazard ratio = 1.739; 95% confidence interval, 1.059-2.857; P = .029). Significant associations were found between high Ang2 and advanced Binet stages (P < .001), high β2-microglobulin (P < .001), unmutated variable region of immunoglobulin heavy chain gene status (P < .001), high CD38 and ζ-chain-associated protein kinase 70 expression (P < .001 and P = .003), and intermediate/high cytogenetic risk (P = .005). Moreover, Ang2 added prognostic power to other conventional prognosticators and helped to refine prognosis among CLL subsets with both high and low vascular endothelial growth factor plasma levels. Ang2 plasma level may be a useful independent prognosticator for CLL.
- Published
- 2010
14. Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status
- Author
-
Goretta Bonacorsi, Elena Morandi, Patrizia Zucchini, Francesca Giacobbi, Roberto Serra, Paola Temperani, Paola Silingardi, Giuseppe Torelli, Marcella Fontana, Am Colacci, Laura Masini, Roberto Marasca, Rita Santachiara, Rossana Maffei, Silvia Martinelli, Ilaria Castelli, Maffei R., Marasca R., Martinelli S., Castelli I., Santachiara R., Morandi E., Zucchini P., Fontana M., Giacobbi F., Silingardi P., Bonacorsi G., Temperani P., Masini L., Colacci A., Serra R., and Torelli G.
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,ANGIOPOIETIN 2 ,Chronic lymphocytic leukemia ,medicine.disease_cause ,Immunoglobulin E ,immunoglobulin heavy-chain mutational status ,Disease-Free Survival ,Angiopoietin-2 ,B-cell chronic lymphocytic leukemia ,prognosis ,immune system diseases ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Mutational status ,Humans ,neoplasms ,Aged ,Aged, 80 and over ,Mutation ,Hematology ,biology ,Angiopoietin 2 ,Middle Aged ,medicine.disease ,Prognosis ,Leukemia, Lymphocytic, Chronic, B-Cell ,Treatment Outcome ,Oncology ,Immunology ,biology.protein ,Immunoglobulin heavy chain ,Female ,Antibody ,Immunoglobulin Heavy Chains ,CLL - Abstract
Our results regarding the adverse prognostic significance of high expression of Ang-2 by CLL cells are substantially in keeping with Hu¨ttmann et al. Importantly, in our series, CLL patients expressing at diagnosis high levels of Ang-2 usually had more advanced clinical stage and a higher percentage of CD38þ cells, had unmutated immunoglobulin status and unfavorable cytogenetics and had a shorter progression-free survival. These associations support the idea of the involvement of Ang-2 in the mechanisms of CLL disease progression. In addition, both circulating and BM-infiltrating Ig-unmutated CLL B-cells are able to express higher levels of Ang-2 than Ig-mutated CLL and normal B cells, suggesting the presence of an intrinsic defect in Ang-2 expression that could be pathogenetically relevant in CLL marrow microenvironment and could be involved in the differential clinical behavior of Ig-mutated and Ig-unmutated CLL cases.
- Published
- 2007
15. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
- Author
-
Maffei R, Fiorcari S, Bulgarelli J, Rizzotto L, Martinelli S, Rigolin GM, Debbia G, Castelli I, Bonacorsi G, Santachiara R, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, and Marasca R
- Subjects
- Female, Humans, Lenalidomide, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Thalidomide therapeutic use, Angiogenesis Inducing Agents metabolism, Angiogenesis Inhibitors therapeutic use, Cell Survival, Endothelial Cells pathology, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Thalidomide analogs & derivatives
- Abstract
Lenalidomide is an IMID immunomodulatory agent clinically active in patients with chronic lymphocytic leukemia (CLL). We evaluated the activity of lenalidomide inside an in vitro coculture system of endothelial and CLL cells. Lenalidomide was able to inhibit CLL survival advantage mediated by endothelial contact. Moreover, the marked increase of in vitro angiogenesis determined by CLL-derived conditioned media was reduced by lenalidomide. We also analyzed peripheral blood collected from 27 patients with relapsed or refractory CLL being treated with lenalidomide within a phase II trial. Plasma levels of VEGF and THBS-1 decreased, whereas Ang2 and Ang increased during treatment. Patients who respond to lenalidomide showed a more pronounced decrease of VEGF and bFGF than did patients with stable or progressive disease (p = 0.007 and p = 0.005). Furthermore, lenalidomide reduced circulating endothelial cells and endothelial progenitors by increasing the percentage of apoptotic cells. Conversely, for six matched bone marrow biopsies available before and after treatment, we did not detect any modification in vessel density, suggesting a possible mechanism of vessel normalization rather than regression. In conclusion, our study provides further evidence that the anti-CLL effect of lenalidomide is mediated through the alteration of microenvironmental elements, implying the modulation of several angiogenesis-related factors and disruption of CLL crosstalk with endothelial cells., (Copyright © 2014 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
16. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.
- Author
-
Maffei R, Martinelli S, Santachiara R, Rossi D, Guarnotta C, Sozzi E, Zucchetto A, Rigolin GM, Fiorcari S, Castelli I, Fontana M, Coluccio V, Leonardi G, Zucchini P, Tripodo C, Cuneo A, Gattei V, Del Poeta G, Forconi F, Gaidano G, Torelli G, and Marasca R
- Subjects
- Adult, Aged, Aged, 80 and over, Angiopoietin-2 analysis, Biomarkers, Tumor blood, Blood Chemical Analysis, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell blood, Male, Middle Aged, Neoadjuvant Therapy, Prognosis, Survival Analysis, Time Factors, Angiopoietin-2 blood, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Leukemia, Lymphocytic, Chronic, B-Cell therapy
- Abstract
The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive of reduced TTFT (P < .001) and overall survival (P = .002). Multivariate analysis confirmed that high Ang2 was an independent prognosticator for TTFT (hazard ratio = 1.739; 95% confidence interval, 1.059-2.857; P = .029). Significant associations were found between high Ang2 and advanced Binet stages (P < .001), high beta(2)-microglobulin (P < .001), unmutated variable region of immunoglobulin heavy chain gene status (P < .001), high CD38 and zeta-chain-associated protein kinase 70 expression (P < .001 and P = .003), and intermediate/high cytogenetic risk (P = .005). Moreover, Ang2 added prognostic power to other conventional prognosticators and helped to refine prognosis among CLL subsets with both high and low vascular endothelial growth factor plasma levels. Ang2 plasma level may be a useful independent prognosticator for CLL.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.